Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 6/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308775 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACEMMECPA1 | |
| SCHEMBL308606 | 0.87 | CYP1A2 (0.60) | NAALAD2ACEMMECPA1ACE2 | |
| SCHEMBL308605 | 0.87 | CYP1A2 (0.60) | NAALAD2ACEMMECPA1ACE2 | |
| SCHEMBL28154840 | 0.86 | CA2 (0.47) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL17491827 | 0.86 | CA2 (0.47) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL6372432 | 0.84 | CTSL (0.56) | FOLH1NAALAD2ACEMMECPA1 | |
| SCHEMBL6372435 | 0.84 | CTSL (0.56) | FOLH1NAALAD2ACEMMECPA1 | |
| SCHEMBL547121 | 0.82 | FOLH1 (0.61) | FOLH1NAALAD2ACEMMECPA1 | |
| SCHEMBL1287829 | 0.82 | FOLH1 (0.61) | FOLH1NAALAD2ACEMMECPA1 | |
| SCHEMBL547122 | 0.82 | FOLH1 (0.61) | FOLH1NAALAD2ACEMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746912-A1 | ORGANIC CYTOTOXIN OLIGOMERS AND USES THEREOF AS A PAYLOAD IN ANTIBODY-DRUG CONJUGATES | Simris Biologics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250255945-A1 | CLICK CHEMISTRY HLA POLYPEPTIDES | IMMUNEO Therapeutics GmbH (DE) | 2025-08-14 | — | — | US | disclosed |
| EP-4599844-A1 | CLICK CHEMISTRY HLA POLYPEPTIDES | Immuneo Therapeutics GmbH (DE) | 2025-08-13 | — | — | EP | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4577248-A1 | A METHOD OF MODIFYING AN ORGANIC CYTOTOXIN FOR USE AS A PAYLOAD IN AN ANTIBODY-DRUG CONJUGATE AND MODIFIED ORGANIC CYTOTOXINS DERIVED THEREFROM | Simris Biologics GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-119789876-A | Method of modifying organic cytotoxins for use as payloads in antibody-drug conjugates and modified organic cytotoxins derived therefrom | 辛利斯生物制药有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2025021727-A1 | ORGANIC CYTOTOXIN OLIGOMERS AND USES THEREOF AS A PAYLOAD IN ANTIBODY-DRUG CONJUGATES | SIMRIS BIOLOGICS GMBH (DE) | 2025-01-30 | — | — | WO | disclosed |
| EP-4494656-A1 | ORGANIC CYTOTOXIN OLIGOMERS AND USES THEREOF AS A PAYLOAD IN ANTIBODY-DRUG CONJUGATES | Simris Biologics GmbH (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006071840-A2 | FORMULATIONS OF HUMAN GROWTH HORMONE COMPRISING A NON-NATURALLY ENCODED AMINO ACID | AMBRX, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | AMBRX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005074650-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | AMBRX, INC. (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | IFNG, IFNAR1, EIF2AK2 | FOLH1 444/4885NAALAD2 221/4885ACE 1595/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | FOLH1 236/4885NAALAD2 64/4885ACE 1434/4885 |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | GHRHR, VEGFA, SHBG | FOLH1 150/4885NAALAD2 769/4885ACE 2817/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | FOLH1 177/4885NAALAD2 122/4885ACE 3162/4885 |
| US-20250255945-A1 | CLICK CHEMISTRY HLA POLYPEPTIDES | MICA, HLA-DRB1, CD74 | FOLH1 256/4885NAALAD2 1116/4885ACE 2371/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | FOLH1 640/4885NAALAD2 106/4885ACE 1686/4885 |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | FGF1, FGF2, FGF23 | FOLH1 80/4885NAALAD2 1184/4885ACE 2870/4885 |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | GHITM, HDGF, GHRHR | FOLH1 103/4885NAALAD2 321/4885ACE 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.